Drug intelligence / Profile preview

Remergent

Development stage
Unknown
Lead developer
Applied Genetics Inc. Dermatics
Modality
Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

Remergent is a brand of topical dermatological products primarily recognized for its DNA repair technology, which utilizes the enzyme **T4 endonuclease V (T4N5)**. Developed by AGI Dermatics, the T4N5 liposome lotion (clinically known as Dimericine) is designed to enhance the skin's natural nucleotide excision repair (NER) pathway. The enzyme is encapsulated in pH-sensitive liposomes that facilitate its delivery into keratinocytes, where it specifically identifies and initiates the repair of cyclobutane pyrimidine dimers (CPDs)—the primary DNA lesions caused by ultraviolet (UV) radiation. By repairing these dimers, the product aims to reduce the mutational burden that leads to skin carcinogenesis. The T4N5 formulation was extensively studied in Phase 2 and Phase 3 clinical trials for the prevention of skin cancer in high-risk populations, such as patients with Xeroderma Pigmentosum (XP) and those with actinic keratosis. Following the acquisition of AGI Dermatics by Estée Lauder, the technology has been integrated into high-end cosmeceutical lines, though it remains a significant example of enzyme-based photoprotection.

Brand names
RemergentRemergent DNA RepairRemergent HQRemergent Barrier Repair
Other names
T4 endonuclease V liposomesT-4 endonuclease V liposomesT 4 endonuclease V liposomesDimericine
02

Targets

DNA

Beyond the preview

Go deeper on Remergent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remergent.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call